Catalyst Pharmaceutical CPRX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent?
- Catalyst Pharmaceutical (CPRX) reported comprehensive income (loss), net of tax, attributable to parent of $63.74M in Q1 2026.
- How has Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent increased by 12.5% year-over-year, from $56.66M to $63.74M.
- What is the long-term trend for Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's comprehensive income (loss), net of tax, attributable to parent has grown at a 52.8% compound annual growth rate (CAGR), from $39.3M to $214.26M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This is a broad measure of financial performance that includes both net income and other gains or losses that bypass the traditional income statement. It provides a more holistic view of the change in shareholder equity resulting from all non-owner transactions during a specific period. Investors use this to evaluate the total economic impact of both operational results and external market factors on the company's value.